Boys, boys, stop fighting. My take: Pharmacan spent too much on small stakes in small players and did little to add value to them. At current market cap, it has lost about 75% of it raised way back when.
You can take that as terrible, and it's certainly not great, but you'd also have to think what they own is worth more than $11m if they fire-saled it so, really, it's kind of a buy.
The company isn't about to self destruct. But there's going to be increasing pressure on Rosen to deliver value for shareholders. Tweed is licking its lips.